Trials / Completed
CompletedNCT02618629
Mass Balance and Metabolism Study of 14C-Z-215
A Phase I Mass Balance and Metabolism Study of 14C-Z-215 in Healthy Male Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- Zeria Pharmaceutical · Industry
- Sex
- Male
- Age
- 35 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The aim of this Phase I study is to determine the absorption, metabolism, and excretion of 14C-Z-215 in healthy male subjects following a single oral administration at a therapeutically relevant dose level (20 mg).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 14C-Z-215 | Single oral dose of 20mg Z-215 and 14C-Z-215 solution |
Timeline
- Start date
- 2016-01-01
- Primary completion
- 2016-06-01
- Completion
- 2016-09-01
- First posted
- 2015-12-01
- Last updated
- 2016-09-22
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT02618629. Inclusion in this directory is not an endorsement.